Lilly's lung cancer drug fails late-stage study

Oct 10 (Reuters) - Eli Lilly and Co said on Tuesday its drug to treat non-small cell lung cancer failed to meet the main goal of improving overall survival in patients in a late-stage study.

Lilly's abemaciclib, however, showed some evidence of improvement in the secondary goals, the company said. (Reporting by Divya Grover in Bengaluru; Editing by Maju Samuel)